>We thought initially the ATRYN market in Europe is just 'proof of concept' but it obviously has ballooned to a lucrative proposition especially on the pricing side.<
The HD indication in Europe is still essentially a proof of concept for GTC’s technology. Even at the price premium to plasma-derived AT, the sales for HD will be relatively small and Leo gets most of the profit.
Market Data 
Markets 
AI
